Suppr超能文献

非酒精性脂肪性肝病进展的人类肝脏基因表达特征:一项荟萃分析。

Human hepatic gene expression signature of non-alcoholic fatty liver disease progression, a meta-analysis.

机构信息

Cardiovascular and Metabolic Diseases, Translational Sciences, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Pepparedsleden 1, Mölndal, 431 83, Sweden.

出版信息

Sci Rep. 2017 Sep 27;7(1):12361. doi: 10.1038/s41598-017-10930-w.

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a wide-spread chronic liver condition that places patients at risk of developing cardiovascular diseases and may progress to cirrhosis or hepatocellular carcinoma if untreated. Challenges in clinical and basic research are caused by poor understanding of NAFLD mechanisms. The purpose of current study is to describe molecular changes occurring in human liver during NAFLD progression by defining a reproducible gene expression signature. We conduct a systematic meta-analysis of published human gene expression studies on liver biopsies and bariatric surgery samples of NAFLD patients. We relate gene expression levels with histology scores using regression models and identify a set of genes showing consistent-sign associations with NAFLD progression that are replicated in at least three independent studies. The analysis reveals genes that have not been previously characterized in the context of NAFLD such as HORMAD2 and LINC01554. In addition, we highlight biomarker opportunities for risk stratification and known drugs that could be used as tool compounds to study NAFLD in model systems. We identify gaps in current knowledge of molecular mechanisms of NAFLD progression and discuss ways to address them. Finally, we provide an extensive data supplement containing meta-analysis results in a computer-readable format.

摘要

非酒精性脂肪性肝病 (NAFLD) 是一种广泛存在的慢性肝脏疾病,使患者面临心血管疾病的风险,如果不治疗,可能会进展为肝硬化或肝细胞癌。临床和基础研究的挑战是由于对 NAFLD 机制的了解不足造成的。本研究的目的是通过定义可重复的基因表达特征来描述人类肝脏在 NAFLD 进展过程中发生的分子变化。我们对发表的人类基因表达研究进行了系统的荟萃分析,这些研究涉及 NAFLD 患者的肝活检和减肥手术样本。我们使用回归模型将基因表达水平与组织学评分相关联,并确定了一组与 NAFLD 进展具有一致关联的基因,这些基因在至少三个独立研究中得到了复制。该分析揭示了以前在 NAFLD 背景下尚未表征的基因,例如 HORMAD2 和 LINC01554。此外,我们还强调了用于风险分层的生物标志物机会和可用于研究模型系统中 NAFLD 的已知药物。我们确定了目前对 NAFLD 进展分子机制的认识存在差距,并讨论了解决这些差距的方法。最后,我们提供了一个包含可机读格式的荟萃分析结果的广泛数据补充。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0ef/5617840/0cc771d0fccc/41598_2017_10930_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验